Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cognis expands production of active ingredients in France

This article was originally published in Scrip

Executive Summary

Cognis, a supplier of speciality chemicals and nutritional ingredients, has invested around €7 million into the extension of its R&D and production site for active ingredients in Pulnoy, France. The project, which was driven by increasing demand for active ingredients for cosmetics, should be completed in 2010. The site in Pulnoy belongs to Laboratories Serobiologiques (LS), Cognis's subsidiary since April 1999, which specialises in the development, manufacture and marketing of active ingredients (mostly for the cosmetic industry). Cognis is based in Monheim, Germany, and employs 7,600 people in 30 countries. It was part of Henkel, a German consumer products company, until 1999, when it became an independent business unit. Henkel sold the unit to private equity funds two years later.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC032133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel